What is actually encryption software?

Cryptography DNA

Cryptography DNA

encryption algorithms

encryption algorithms

Encryption Software

Encryption Software


— Ramon Mora

NEW YORK, NEW YORK, UNITED STATES, January 19, 2021 /EINPresswire.com/ — What is actually encrypting software?

In today's digital and fast-paced world, encryption software is must-have if you are dealing with storing data that needs to be far away from prying eyes. But what exactly is encryption software?

It's a powerful tool, that is, a security program in charge of protecting your data. To put it simply, it is a method by which your information is converted into secret code. These secret codes are hiding the true meaning of information, and they are almost impossible to crack.
The science of encrypting/decrypting information is called cryptography.

Why you should use encryption software?
People's confidence on the Internet is on the decline. The reasons for this are quite obvious. But let's make one thing crystal clear. Your privacy and all personal data are 24/7 at risk of falling into the wrong hands. This is particularly concerning when it comes to financial information or other private file exchanging.

Encryption of data files
Encryption is the best possible way to keep all sending or receiving data over the internet safe, away from the eyes of other people, confidential. That can include credit card details, private chats with your friends or colleagues, passwords, or simple pictures you want to share with relatives and friends.

So once again, bear in mind that keeping these files out of other people's hands demands encryption software.
Encryption software converts, or let's better say transform your information into a massive confusing series of something that looks like a mess. Every single letter and number of your data is converted through an algorithm before getting in the hands of the recipient.

This brings us closer to the clear answer to the question of what is encryption software.
Encryption software importance
Encryption plays a great role in protecting a wide range of information technology assets. Encryption provides the following:
• Confidentiality encodes the content of your messages
• Authentication verifies the message origin
• Integrity ensures that message content has not been changed
• Nonrepudiation prevent message sender from denying they sent it

The way encryption software works
Now that we understand the basic concept of software encryption, let's take a closer insight into how it works. First things first, you do not need separate software for decrypting previously encrypted files because one single program can do both functions.

The very beginning of a message traveling through encryption software begins with a key. This is not a real physical key. It is a long string of zeroes and ones. Software algorithm generates a customized unique key based on which your information is scrambled.

These algorithm keys can be used for both decryption and encryption. But over the years, they are separated to increase security. As you can guess, the more complex the key is, the harder it is for intruders to crack it.

The takeaway
Data transfer, email encryption, and messenger encryption software are evolving daily. Engineers are constantly working hard on faster encryption methods.
All in all, encryption gain huge momentum, especially last years, as hackers are constantly finding ways to steal data.

Ramon Mora
Corporacion Advisor
+ +1 3058965896
email us here
Visit us on social media:

Source: EIN Presswire

Interventional Orthopedics Connecticut Provide An Expert Opinion: 7 TRUTHS About Stem Cell Therapy

Interventional Orthopedics Connecticut Logo

Interventional Orthopedics Connecticut Logo

Dr Southern explaining stem cell therapy injection to a patient CT

Dr Southern explaining stem cell therapy injection to a patient

With the amount of information out there about stem cell therapy, it can be difficult to find the truth. Dr. Daniel Southern, M.D. weighs in and debunks myths.

WILTON, CT, 06897, January 19, 2021 /EINPresswire.com/ — The experts from Interventional Orthopedics Connecticut are stating to the public the truth surrounding stem cell therapy. It's a relatively new treatment, and the questions continue to pour into the office about what stem cells do, if they are safe, and how stem cells actually work. Here are a few of the most popular subjects with detailed answers for anyone considering stem cell therapy in Connecticut.

1. Where Are Stem Cells Collected From?
Stem cells are obtained from various parts of the body. Interventional Orthopedics isolates the stem cells from multiple tissues such as bone marrow from a donor's blood or umbilical cord blood when a baby is born.

Circulating blood is another way certified physicians obtain stem cells. Amniotic fluid, where a fetus develops in the womb, is a commonplace to collect stem cells and is a standard way to treat babies born with congenital disabilities.

Doctors educated and trained in stem cell collection, like Dr. Southern at Interventional Orthopedics Connecticut, know the safest and most effective methods for collecting stem cells.

2. How Do Stem Cells Work?
Stem cells work by helping to replenish specific cells that were previously damaged. Through a differentiation process, one type of stem cell can repair various other types of cells within the body.

For example, a stem cell that has been collected and injected into a patient with a bone break or cartilage damage would recover more quickly. The stem cells are introduced and start working faster than the body's rate of replenishing them. Some uses of stem cells include: Replacing damaged tissues or organs, fixing parts of organs that aren't functioning correctly, pain treatment, and disc problems

Stem cell therapies are increasing in popularity, especially among athletes and those who don't want to be on restrictions for longer than necessary. It's an alternative to more invasive methods like surgery.

3. Are Stem Cell Injections Safe?
The majority of patients that have received stem cell injections have zero to minimal side effects. The stem cells are first gathered from that person, so the likelihood of any adverse reaction is minimal. The most frequent complaints are minor aches and swelling.

4. Is Stem Cell Preservation Possible?
Stem cell preservation is possible. Stem cells are often collected from umbilical cords during the birth of a baby, as mentioned previously, and those have been successfully protected and utilized in patients for many years.

There has been stem cell data obtained on units collected from umbilical cord blood for 25 years. From that collected information, tests have shown that stem cells from the blood didn't deteriorate in samples frozen for 16 years and transplanted after 13 years.

5. Can Stem Cells Help Arthritis?
Yes! Arthritis is one condition that is considered among the top for patients looking for stem cell therapies. The non-surgical treatment gets those that are suffering back to their average activity level without an operation in most cases.

Some of the types of arthritis that the professionals from Interventional Orthopedics Connecticut perform treatment for include osteoarthritis, ankle arthritis, neck arthritis, hip arthritis, low back arthritis, knee arthritis, and shoulder arthritis.

Those that have received a stem cell therapy procedure for arthritis have often reported relief after just one session.

6. What Are Other Important Uses for Stem Cells?
Stem cells are often collected strictly for research in laboratories. Scientists, health experts, and other professionals continuously alter, grow, and test stem cells to determine additional uses. Stem cells have also been used for cancer treatments and genetic blood disorders in both adults and humans.

7. Are There Any Negative Effects of Stem Cell Therapy in Connecticut?
As with most medical treatments, stem cell therapy comes with the potential of side effects. There have been few reports of adverse effects of stem cell therapy. Patients have complained of pain in the mouth and throat with some inflammation and sores. Also, nausea and vomiting, infection, lung problems, and ineffectiveness have been documented as undesirable side effects.

You can get a clearer idea of the risks associated with stem cell therapy and the success rate by speaking to the specialists at Interventional Orthopedics Connecticut. The specifics of the treatment you are seeking out will vary from the person that comes in before you and the one after. Your doctor will give you more concrete statistics about your stem cell therapy type unique to your health condition.

If you're interested in learning more about stem cell therapy from Interventional Orthopedics Connecticut, the staff encourages you to call to speak with a knowledgeable specialist. Many initial appointments are being arranged virtually or over the phone. You can reach them at (203) 456-5717.

Their team has also put together an extremely informational, user-friendly website for further research. Explore the possibilities of stem cell treatments by visiting https://www.regenerativeorthopedicmedicinect.com/.

About Interventional Orthopedics Connecticut

Daniel Southern, M.D. manages Interventional Orthopedics Connecticut. Dr. Southern is interventional orthopedic and sports medicine physiatrist in Connecticut. He is board-certified in pain medicine, sports medicine, and through the American Board of Physical Medicine and Rehabilitation Physiatry.

Daniel Southern, M.D. is passionate about alternative methods for pain and musculoskeletal injuries. Some of the services offered are intended for athletes and those suffering from chronic pain who prefer to avoid more invasive surgeries. Dr. Southern is recognized as one of the best in interventional orthopedics in Connecticut and throughout the country.

The friendly and highly-educated office staff is just as passionate about alternative treatment options. They are available to answer questions and set up appointments.

Dr. Daniel Southern, M.D.
Interventional Orthopedics CT
+1 203-456-5717
Visit us on social media:

Intro Interventional Orthopedics CT | Non Surgical Treatment for Injury & Arthritis

Source: EIN Presswire

Smithsonian and Cricket Media Launch the 10th Annual Spark!Lab Dr. InBae Yoon Invent It Challenge for Kids Worldwide

Invent It Challenge 2021 banner

The creativity of the Invent It Challenge winners points the way to a more inventive future for all.”

— Sharon Klotz, Lemelson Center's Head of Invention Education

WASHINGTON, DC, USA, January 19, 2021 /EINPresswire.com/ — On November 23, 2020, Smithsonian launched the 10th annual global Spark!Lab Dr. InBae and Mrs. Kyung Joo Yoon Invent It Challenge. Today, in celebration of Kid Inventors’ Day, Cricket Media, in partnership with the Smithsonian's Lemelson Center for the Study of Invention and Innovation, honors the critical role children play in sparking innovation worldwide. The Invent It Challenge offers eligible children the opportunity to showcase their creative thinking on a global stage. Thanks to the generosity of the Yoon family, winners of the annual Challenge in each category will participate in a multi-day visit to the Smithsonian's National Museum of American History in Washington, D.C. (USA), during which they will undertake invention collaborations and get an exclusive look at the Museum's invention collections. Individual students, entire classrooms, schools, and other organizations serving children between the ages of 5-18 are encouraged to participate. 

This year's Challenge invites kids to become "game-changing" inventors who transform how we play and engage with sports. Young inventors are guided to think critically about sports from different perspectives and solve challenging problems: what inventions are needed to make sports more fun and accessible to people of all abilities, ensure fairness in competition, ensure the safety and health of athletes, and push athletes to greater heights and achievement? "Educating and inspiring the next generation of inventors requires access to role models and learning resources that share how real-life problems are tackled and solved," says Laura Woodside, Senior Vice President Education Products at Cricket Media. "We are proud to once again join with the Smithsonian's Lemelson Center and Spark!Lab to empower students across the globe to make a real difference in the world."

The 2020 Challenge theme was "how to improve access to healthy food," and participants were challenged to create an invention that improved access to healthy food by changing how it is produced, distributed, selected, stored, and prepared, as well as made more affordable. Hundreds of children ages 5-18 participated in the Challenge, and winning inventions included a ship that uses reverse osmosis and hydroponics to safely and scalably grow healthy food in urban ports, a stacking device that helps protect food in transit and a disposable utensil made from avocado stone that simultaneously reduces waste and seeds new plants in the environment. "Inventive habits of mind – which include curiosity, resourcefulness, resilience, risk-taking, and comfort with complexity and ambiguity – cut across all domains and disciplines and aren’t constrained by gender, age, or any other variable. The creativity of the Invent It Challenge winners points the way to a more inventive future for all.” says Sharon Klotz, Lemelson Center’s Head of Invention Education.

 The Spark!Lab Dr. InBae Yoon Invent It Challenge requires students to follow seven key steps in the invention process: identifying the problem, conducting research, sketching their ideas, building a prototype, testing the product, refining it, and communicating about it to potential users. The process helps to cultivate and reinforce process skills underlying inquiry, creativity, and innovation as well as content themes across science, technology, engineering, math, the arts, history, economics, and other domains. The deadline for submitting inventions to the Challenge is April 17, 2021. A panel of Smithsonian and Cricket Media judges will select winners. For complete entry guidelines and Official Rules, visit https://inventitchallenge.com.


Cricket Media, Inc. is a global education company providing award-winning content and safe and secure collaborative learning networks. Cricket Media serves millions of teachers, students and parents in over 200 countries and territories to fulfill its mission to engage, enlighten and educate children everywhere. Learn more at www.CricketMedia.com.

Spark!Lab is a hands-on invention activity space operated by the Jerome and Dorothy Lemelson Center for the Study of Invention and Innovation at the Smithsonian's National Museum of American History. The Lemelson Center engages, educates, and empowers the public to participate in technological, economic, and social change. Through historical research, educational initiatives, exhibitions, and public programming the Centers advances new perspectives on invention and innovation and fosters interactions between the public and inventors. For more information, please visit http://invention.si.edu/try/sparklab.

Laura Woodside
Cricket Media
+1 703-885-3417
email us here

Source: EIN Presswire

New Year Equals new Opportunities to Stay on top of Your Health

Men’s Health Network

Please consider publishing the following Men's Health Network press release entitled "New Year Equals New Opportunities To Stay On Top Of Your Health."

WASHINGTON, DISTRICT OF COLUMBIA, UNITED STATES, January 19, 2021 /EINPresswire.com/ — New Year Equals New Opportunities To Stay on Top Of Your Health

You know what they say: New Year equals a new me, right?

Well, despite the overwhelming feeling of relief by many that our calendars have flipped from 2020 to 2021, it is absolutely vital to both men and women to make a plan to stay on top of their health.

Some could read that last line and say to themselves: well, how can I go about doing that?

Glad you asked. First and foremost, it's good to keep a checklist to know what exactly you should get screened for. Thankfully, if you don't where to start, the Men's Health Network has got you covered.

Dr. Salvatore Giorgianni, Jr., a senior science advisor for Men’s Health Network, says it's very hard to make a one general recommendation on which ones to prioritize because the screenings need to be done based on the underlying physical condition of that particular person.

"For most guys – regardless of age or condition – they should have a yearly examination by a qualified healthcare provider. Then, based on what is found during the general physical recommendations for periodic self-monitoring and medical office monitoring will be made," Dr. Giorgianni said. "If any generalized condition is found, for example, high blood pressure or irregular heart beat, a combination of self-monitoring and periodic check-ups every 3-6 months may be warranted. Sometimes these check ups may need to be more frequent when starting a new treatment to see how the response is."

Of course, the 'typical' screenings such a blood pressure and physical examinations for both women and men are on there, this online resource is broken down for both women and men, ranging from PAP tests to prostate exams and everything in between.

MHN's checklist is broken down by gender and age group, starting from ages 20-39, 40-49, and 50-plus. According to Dr. Giorgianni, things change once you get older.

"For older guys, for example those over 60 or 65 years of age, even in general good health, a check-up every 6 months or so is a good idea as things tend to change more rapidly as we get older.," Dr. Giorgianni said.

After you download this handy checklist, talk to your health care provider and stay on top of your health for 2021 and beyond.

Get it checked.

Men's Health Network

Men's Health Network (MHN) is an international non-profit organization whose mission is to reach men, boys, and their families where they live, work, play, and pray with health awareness messages and tools, screening programs, educational materials, advocacy opportunities, and patient navigation. Learn more about MHN at www.MensHealthNetwork.org and follow them on Twitter @MensHlthNetwork and Facebook at www.facebook.com/menshealthnetwork. Consider donating to MHN at www.menshealthnetwork.org/donate.

Brandon Ross
Men's Health Network
+1 202-543-6461 ext. 101
email us here

Source: EIN Presswire

Nutrition Research Institute Scientist Part of International Team Researching the Composition of the Human Microbiome

KANNAPOLIS, NORTH CAROLINA, UNITED STATES, January 19, 2021 /EINPresswire.com/ — Katie Meyer, Sc.D., is one of many UNC Nutrition Research Institute (NRI) faculty members leading her field through innovative research. Recent technological advances are allowing researchers such as Meyer and her team to substantially broaden our knowledge of the human microbiome, the microbial ecosystem that inhabit the internal and external surfaces of our bodies. The trillions of microbes living with us are not just passengers ‒ they actively participate in many human functions, helping us to digest food, training our immune system and even affecting our mood via the gut-brain axis.

The largest and richest human microbiome inhabits the gut and contributes substantially to our health. Yet the factors that shape its composition, although widely studied, remain unclear, and the more than 80% difference in gut microbiome between individuals remains unexplained. In general, environmental factors such as diet and medication play a major role, however a role for human genetic variants has also been suggested by the identification of heritable bacteria, i.e. those that are more common in twins and family members.

Now, a new study from the MiBioGen consortium, an international collaboration involving more than 20 labs across the world, including the Meyer lab at the UNC NRI, and led by researchers at the University Medical Center Groningen, highlights the common host genetic factors that influence the composition of the human gut microbiome in >18,000 people analysed. They report that at least two human genes have a major impact in shaping our gut ecosystem: the lactase gene (LCT), which influences the abundance of lactose-digesting Bifidobacteria, and the fucosyl transferase (FUT2) gene, which determines the abundance of Ruminococcus torques. They also show that other human genes affecting microbiome composition are involved in important aspects of host metabolism, nutrition and immunity. Their analyses stretch as far as establishing relationships between several bacterial species and human diseases. For example, a higher abundance of Bifidobacterium decreased the risk of the inflammatory bowel disease ulcerative colitis, an observation also reported in previous clinical trials.

“This study is a great example of a large international collaboration and is the first to accurately estimate the effect of host genetics on the gut microbiome,” explains Alexandra Zhernakova, one of the principal investigators leading the consortium. “More genetic effects will likely be identified with increased sample size in future studies, but our multi-centre approach did identify robust loci that are shared across populations. However, further studies in large and more homogenous groups are essential to identify population-specific effects and gene-environmental interactions.”

“It was a challenge to combine datasets from multiple cohorts due to the large technical differences and to biological variations across populations. However, this diversity also brings strength – for example, we could see that genetic variants in the lactase gene determine Bifidobacteria abundance in adults, but not in children, and that this effect is more pronounced in European populations,” says Alex Kurilshikov, the first author of the study. “The large sample size also allowed us to apply genetic methods and show that some bacteria are causal for developing diseases.”

Meyer and colleagues from the National Institute on Aging (Lenore Launer) and the Health Science Center at Houston, The University of Texas (Myriam Fornage) contributed participant genetic and gut microbiota data from the bi-racial population-based Coronary Artery Risk Development in Young Adults (CARDIA) study.

The MiBioGen researchers have made their results available to other scientists and the scientific community for additional and future analyses. All results are uploaded to http://mibiogen.org, supported by the Genomics Coordination Center in the Department of Genetics, UMCG.

The publication in Nature Genetics is available at https://www.nature.com/articles/s41588-020-00763-1

About the UNC Nutrition Research Institute

The UNC Nutrition Research Institute’s mission is to advance the field of precision nutrition by investigating how genetics, gut microbiota, and environment affect an individual’s requirements for and responses to nutrients. Every person is metabolically unique. The NRI is dedicated to finding out how these differences affect an individual’s health so that current one-size-fits-all dietary guidelines can be replaced with customized nutritional recommendations and actions to improve a person’s health and quality of life.

For more information on the Nutrition Research Institute or to schedule an interview, contact Suzanne Dane, Director of Community Outreach and Development.

Suzanne Dane
UNC Nutrition Research Institute
+1 704-250-5008
email us here
Visit us on social media:

Source: EIN Presswire

Pain Care Labs Receives 2020 Tibbetts Award for Innovation

Amy Baxter MD

Dr. Amy Baxter, Medical Doctor and Pain Researcher

The industry leader in drug-free pain relief joins a select group of past awardees, including Qualcomm, 23andMe, Symantec, and Broadcom.

Pain Care Labs innovations have led to a new category of pain relief, which has led to extensive independent, unfunded research supporting their technology.”

— Julie Collins, Former Director, SBIR GA

ATLANTA, GA, UNITED STATES, January 19, 2021 /EINPresswire.com/ — Pain Care Labs, the industry leader in noninvasive, drug-free pain relief solutions, announced its selection as a 2020 Tibbetts Award winner. The award recognizes the substantial economic and social benefits the company’s pain-relieving medical devices have contributed to our nation by leveraging funding from National Institutes of Health (NIH) Small Business Innovation Research (SBIR) programs.

After initial prototyping in the scientist-founder’s basement, Pain Care Labs has worked hand-in-glove with NIH research institutes. “In 2009, the National Institute of Child Health and Human Development believed in a small, all-woman business, and cared enough about vaccination pain to fund a pediatrician’s theory,” recalls Amy Baxter M.D., pediatric emergency physician and CEO of Pain Care Labs. “Our program officer was patient, passionate, and elevated the level of our science. Since that time, various program officers in the NIA, NIDA, NINDS, and other SBIR liaisons have graciously given their time and acumen to expand the business and science scope of our company.”

Pain Care Labs’ mission – to eliminate unnecessary pain – exhibits the kind of public health benefit and company investment that the SBIR program was designed to support. “As a WBENC-certified company, they have practiced inclusion and diversity,” observes Julie Collins, Former Director, SBIR GA, Innovation Coach, and NSF I-Corp Faculty. “Furthermore, their innovations have led to a new category of pain relief, which has led to extensive independent, unfunded research supporting their technology.”

Input from The National Institute on Drug Abuse has enabled Pain Care Labs to look beyond the science to the company's real potential. Dr. Baxter reflects, “SBIR funding has allowed us to expand our indications for use from vaccination and needle pain control to broader drug-free musculoskeletal pain relief.” The NIH approach links the science to the sales, facilitating translation into life-saving technologies. With federal funding provided by the NIH, Pain Care Labs is now developing and investigating a low back pain device to reduce opioid initiation or dependence.

The urgency of vaccination to address the COVID-19 pandemic amplifies Pain Care Labs important work in reducing needle pain and fear. As Renee C.B. Manworren, PhD, APRN, notes, “As we continue to face a pandemic health crisis, I am confident their first product, Buzzy®, will help accelerate worldwide vaccination against this deadly virus.”

About the Tibbetts Awards
The Tibbetts Awards are presented to companies that promote the mission and goals of the SBIR program, which include stimulating technological innovation and increasing commercialization of federal research. The Awards are named after its founder Roland Tibbetts, an active champion of the SBIR cause. He piloted the program and then served as the SBIR Program Manager at National Science Foundation from 1976-1996.

Pain Care Labs is the industry leader in noninvasive pain relief solutions. Buzzy® has been used to block pain for over 37 million needle procedures. VibraCool® is an FDA registered 510(k) cleared device to treat myofascial pain caused by trigger points, restricted motion, and muscle tension. Established in 2006 by emergency physician and pain researcher Amy Baxter M.D., the Company is dedicated to effective, reusable, and affordable solutions for pain. The Company’s award-winning solutions are based on patented Oscillice® M-Stim® , a mechanical stimulation/thermal neuromodulation platform. Pain Care Labs was named "Industry Leader for Localized Pain Relief" by Frost & Sullivan, a leading market research firm. For more information, including a list of published studies, please visit PainCareLabs.com.

Leisha Richardson
+1 512-633-2387
Visit us on social media:

Source: EIN Presswire

Telegenetics in 2021: What to Expect

what is telegenetics

Telegenetics 2021

USA, January 19, 2021 /EINPresswire.com/ — Telehealth

The last few years have been exciting and fast-moving ones in the field of telegenetics and telemedicine. We have seen more and more telegenetics platforms coming to the market and also the development of some exciting AI-based platforms for genetic analysis and diagnosis.

What can we expect from the field of telegenetics in 2021?

A push for greater accessibility

Telegenetics is increasingly well known amongst genetic counselors and geneticists, and at the same time amongst increasing numbers of family physicians. This means that the use of telegenetics platforms is usually initiated by a clinician or doctor.

However, what we are going to see in 2021 is a greater push for accessibility, which allows patients and their families to access telegenetics platforms and diagnostic tools directly. This means patients with concerns and or symptoms of a rare disease can initiate their own genetic analysis. Let’s take the example of the FDNA telehealth platform. This analysis tool allows patients to schedule an online meeting with a genetic expert and allows them to directly upload a photo for facial screening, which will then generate their genetic analysis report.

This, of course, does not mean that we will see the replacement of genetic counselors and geneticists. Their roles will be as important as ever before, if not more so. In fact, this increased accessibility will mean a greater ability to be able to better connect genetic counselors and geneticists with patients directly and remotely, in the process removing obstacles to appointments, and at the same time reducing wait times for consultations.

A drive for comprehensive care

This means that telegenetics will develop, not just to provide a quicker and more accurate diagnosis, but also to provide a more complete 360 view of patients and their care. Using advanced AI technologies to generate genetic reports is an important part of telegenetics moving into 2021, but equally important are platforms that also connect patients with the necessary genetic experts. This is crucial to reach a full and comprehensive diagnosis, while also receiving essential support and assistance with the long-term management of a rare disease.

A greater emphasis on results for the patient, in terms of a diagnosis, involves combining telegenetic technology with the genetic and medical experts who can help patients manage their rare condition most effectively. Solutions that support patients throughout the entirety of their rare disease diagnosis is the future of telegenetics as it strives to deliver better patient care.

FDNA Telehealth’s approach to telegenetics doesn't just involve advanced screening technology. It also includes a network of genetic counselors and geneticists who complement the telegenetics platform.

A clearer path to affordability

Telegenetics in 2021 is set to become much more affordable. This means making it accessible to as many people as possible, with costs coming down and greater coverage by insurance companies. It also means enabling patients more direct access to telegenetics solutions.

A demand for greater accuracy

Accuracy is the watchword for telegenetics for 2021. It won’t just be about faster analysis but will mean much more accurate diagnosis too. There is a real need in the rare disease field to reduce the number of patients misdiagnosed. Research into misdiagnosis and Ehlers Danos, for example, shows that up to 56% of patients with the condition experienced at least one misdiagnosis before receiving a correct one. The only way to do this is with more precise and advanced technology.

FDNA’s platform has already analyzed over 250,000 rare patients and started them on their journey to a much more accurate diagnosis.

This drive for greater accuracy should be at the center of telegenetics in 2021 and beyond.

A real reduction in diagnosis times

The aim of telegenetics in 2021 will definitely be to reduce diagnosis times. Most rare disease patients currently wait, on average, up to 5 years for a correct diagnosis. In the meantime, this means their condition is not managed properly.

When it comes to genetic syndromes, improving patient care means delivering faster diagnosis for patients who so desperately need to be connected to the genetic experts that can provide the answers and support they need.

Continued advancements in AI technologies

Telegenetics in 2021 will see the development and improvement of the technologies driving telegenetics, especially in the field of genetic analysis and diagnosis. From facial screening technology to more advanced online telehealth platforms connecting patients to genetic experts, 2021 is going to be another fast-moving year when it comes to telegenetics technologies.

Telegenetics developed out of a need to make key genetic services more accessible to the patients and families who need these services most. In 2021, we expect to see telegenetics services reaching more patients and bringing more people closer to an accurate diagnosis. This, in turn, will mean a reduction in diagnostic journey times and ensure rare disease patients get the right information, support, care, and treatment for their condition.

Ido Rabiner
FDNA Telehealth
+1 877-327-0735
email us here

Source: EIN Presswire

Squarex Announces End of Phase 2 Meeting with FDA for its Cold Sore Prevention Asset

Typical cold sore infection caused by Herpes simplex virus

Image of the Herpes simplex virus, or herpes labialis, which causes cold sores

Squarex Pharma announced updated results from its successful Phase 2 clinical study on humans with its novel asset SQX770 for prevention of cold sores.

We believe our novel drug SQX770 addresses a large, global unmet clinical need for those people suffering from frequent cold sores due to herpes labialis. This is a $600 million market in the USA.”

— Hugh McTavish

ST PAUL, MINNESOTA, USA, January 19, 2021 /EINPresswire.com/ — Squarex Pharma (SQX), a St. Paul, Minnesota, USA-based company, announced updated results from its Phase 2 clinical study on humans with its novel asset SQX770 for prevention of cold sores, also known as herpes labialis or oral herpes, an illness caused by herpes simplex virus, usually type 1 (HSV-1).

SQX770 is a unique, first in class topical immunomodulator. SQX770 is the only product shown to reduce the number of cold sore events or flareups as well as their severity.

About 50% of the Western population is infected with HSV-1. Herpes outbreaks give rise to cold sores, usually seen as painful sores or blisters around the lips of the patient. Currently there are no preventative treatments, only pills, creams, and ointments to be used once cold sores appear in order to shorten the outbreak. Current drugs do nothing to prevent reoccurrence of outbreaks or reduce the number of outbreaks.

SQX770 addresses a very substantial worldwide market—2.1% of the population has 6 or more outbreaks per year and 15% have 1 or more.

SQX770 is applied topically and has a systemic effect: one topical dose applied with a dermal patch to the upper arm prevents outbreaks for three months. An earlier Phase 1 study at Massachusetts General Hospital in Boston, USA, showed that SQX770 has significant efficacy versus placebo in reducing the recurrence of cold sores.

SQX770 is thought to work by stimulating the sufferer’s immune system via the dendritic cell network in the skin and stimulation of T-cell activity. SQX770 is intended to be available by a doctor’s prescription although ultimately it could be available over the counter in pharmacies.

The Phase 2 study with 139 patients using SQX770 at 5 sites confirmed this in showing reduced number of cold sore outbreaks and further showed reduction in severity of the (fewer) outbreaks that occurred.

Thus, efficacy and safety have been demonstrated in each of two double-blind placebo-controlled clinical trials. A third clinical trial showed significant improvement in cellular immune response to the HSV-1 virus after dosing with SQX770.

Patents covering SQX770 are issued in US, Europe, and Japan until at least 2036 and pending in China, Canada, India, and Australia

Squarex announces that is has completed an End-of-Phase 2 meeting with the U.S. FDA which has provided a clear and achievable path to a New Drug Application in the USA following ultimately a routine Phase 3 study. It will pursue a similar path for regulatory approval in Europe and the rest of the world.

Squarex seeks a global strategic partner with which it can collaborate to exploit its SQX770 drug and take it through final clinical development to market authorisation.

Hugh McTavish, CEO of Squarex, said “Results from patients recruited into our clinical study are very promising; we believe that our novel drug asset SQX770 addresses a large, global unmet clinical need for those people suffering from frequent cold sores due to herpes labialis. Our end of Phase 2 meeting with FDA has been very positive and helpful in pointing the way forward for marketing approval for SQX770. We estimate that the annual market for prevention of oral herpes in the USA is about $600 million.”

For more information about Squarex and partnering opportunities for its Herpes Labialis preventative treatment, please contact:
Dr. Bill Mason
The Sage Group
The Old Black Barns
Lord’s Lane, Ousden CB8 8TX UK
Tel: +44 (0) 7785 950134
Wayne Pambianchi
The Sage Group Inc.
1802 Route 31 North
#381 Clinton
New Jersey 08809 USA
Phone: +1 908 2306170
Hugh McTavish
CEO, Squarex Pharma LLC
Tel: +1 651 4920283
About Squarex Pharma
Squarex is a clinical stage pharmaceutical company which has developed a topical formulation of the immunomodulator squaric acid dibutyl ester for the prevention of recurrent cold sores (herpes labialis) and other infections caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2.

More than 6 Million people in the U.S. alone suffer with 6 or more herpes labialis outbreaks every year with no existing medications indicated for the prevention of outbreaks.

Squarex’s drug SQX770 is unique. A single topical application to the arm, not the lip or face, has been shown in clinical trials to prevent cold sore outbreaks (oral herpes) in people with frequent outbreaks for 3 months.

Website: https://squarex-pharma.com/

About The Sage Group, Inc.

The Sage Group Inc. is a leader in the provision of strategic and transactional advice to health care companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields. Sage currently maintains offices in USA, Europe, Israel and Japan. Since its founding in 1994, The Sage Group has served more than 200 clients in the US, Europe and Asia, and completed numerous transactions including divestitures, alliances, acquisitions and financings with values ranging from $5 million to $500 million.

The Sage Group is an organization of experienced and successful executives who are committed to the service of the very vital and dynamic health care industry and its investors.

The range of services offered includes:
• Strategic alliances and licensing/partnering
• M&A, divestment, buy- and sell- side
• Global product and technology acquisition searches
• Strategic assessment and planning
• Due diligence, technology and molecule assessment, valuation
• New ventures, interim management
• Facilitating investment in R&D and/or company equity through introductions, network and brokering

The Sage Group's Principals, each an Executive Director, have been Founders, Chairmen, Presidents, CEO's and COO's of a number of emerging health care companies. These Principals have also held senior level management positions in large multi-national organizations. In addition to their management backgrounds, The Sage Group's Principals also have extensive experience in providing professional management consulting services to healthcare industry clients. All these experiences are being applied by The Sage Group to assist industry participants in these challenging times.
Website: www.sagehealthcare.com

Dr. Bill Mason
The Sage Group
+44 7785950134

Source: EIN Presswire

Optibrium Enhances Compound Design Strategies in Major Upgrade to StarDrop Software

Optibrium Enters Cheminformatics Collaboration with MSD

Optibrium Enters Cheminformatics Collaboration with MSD

New features include reaction-based library enumeration for novel molecule generation and optimisation, and seamless AI-integration for deeper data analysis

CAMBRIDGE, CAMBRIDGESHIRE, UNITED KINGDOM, January 19, 2021 /EINPresswire.com/ — Optibrium™, a developer of software for drug discovery, today announced the release of the newest version of StarDrop™, a comprehensive software platform for small molecule design, optimisation and data analysis. The new release, StarDrop 7.0, further extends the software’s compound design strategies, provides enhanced workflows, and seamlessly connects with Optibrium’s Cerella™ platform, delivering unique Artificial Intelligence (AI) capabilities to drug discovery scientists. More than 150 organisations worldwide use StarDrop in their research programs – the new features have been developed in close collaboration with key customers and have proven their benefits in identifying optimally balanced, successful and novel compounds faster.

Reaction-based Library Enumeration (RBE) enables chemists to easily enumerate compound libraries and explore optimisation strategies. As a new feature of StarDrop 7.0, RBE delivers a highly-flexible and user-friendly environment to generate new molecules, by applying tractable, robust chemical reactions and linking directly with in-house and commercial building block libraries. Combined with StarDrop’s multi-parameter optimisation capabilities, this enables medicinal chemists to target high-quality and synthetically accessible compounds.

StarDrop 7.0 seamlessly integrates with Cerella, Optibrium’s newly introduced AI software platform, providing intuitive workflows that leverage Cerella’s unique capabilities to accelerate discovery cycles and reduce costs while targeting high-quality compounds. Deploying advanced deep learning methods, Cerella has been demonstrated to extract additional value from compound data, highlighting relationships between structures, activities and other properties on a scale and accuracy unmatched by conventional cheminformatics methods.

Edmund Champness, Optibrium’s Chief Scientific Officer, commented, “Having surveyed the available reaction-based enumeration tools, and found no solutions that met their requirements, our collaborators asked us to develop this feature. We thank them for their input, which was instrumental in shaping an industry-leading capability with the elegance and functionality they’ve come to expect from StarDrop. Added to which, after the successful launch of our AI platform Cerella, we are excited to provide our users with seamless access to a groundbreaking AI system through its integration in StarDrop 7.0.”

For further information on Optibrium, StarDrop 7.0 or Cerella, please visit www.optibrium.com, contact info@optibrium.com or call +44 1223 815900.

Sarah Jeffery
+44 7771 730919
email us here
Visit us on social media:

Source: EIN Presswire

Benchmark testing confirms Made-in-Singapore GK-GermKiller® Concentrate™ is >99.9% effective against SARS-CoV-2 Virus

GermKiller GK Concentrate™ Disinfectant is tested and proven effective against Covid-19 virus

GermKiller GK Concentrate™ Disinfectant Effective against Covid-19 virus

Testing based on US EPA guidelines for virucides confirms GK-GermKiller® Concentrate™ disinfectant effective in breaking the chain of infection of COVID-19

SINGAPORE, January 19, 2021 /EINPresswire.com/ — Vance Chemicals Pte. Ltd. (“Vance Chemicals”) announces today that its GK-GermKiller® Concentrate™ general purpose dilutable disinfectant has been proven scientifically >99.9% effective in inactivating the SARS-CoV-2 virus that is responsible for the ongoing COVID-19 pandemic.

Vance Chemicals subjected GK-GermKiller® Concentrate™ for testing against an actual SARS-Cov-2 strain identified as “Isolate USA-WA1/2020” (1) The “Isolate USA-WA1/2020” strain was isolated from an oropharyngeal swab of a COVID-19 patient in the USA. To ensure the testing adhered to internationally-accepted protocols, the US EPA product performance test guideline ASTM E1053 (2) – Standard Practice to Assess Virucidal Activity of Chemicals Intended for Disinfection of Inanimate, Nonporous Environmental Surfaces, was implemented by a certified US laboratory.

The result: GK-GermKiller® Concentrate™ demonstrates efficacy based on the US EPA passing criteria requirement of at least 3 log10 reduction of SARS-Cov-2. In other words, GK-GermKiller® Concentrate™ can quickly inactivate >99.9% of this virus in a short time.

In addition to social distancing, hygiene is core to limiting the spread of the disease. SARS-CoV-2 is mainly transmitted via respiratory droplets and aerosols from infected persons when they sneeze, cough, speak or breathe, especially when in close proximity with others. Besides direct transmission, infectious droplets that land on surfaces that others touch can cause indirect transmission [3]. SARS-Cov-2 can survive on surfaces ranging from a few hours to 28 days depending on the type of surface and the temperature of the environment [4]. Frequent hand-washing and disinfecting of contact items and surfaces is therefore important. Consequently, this test result confirms that the use of GK-GermKiller® Concentrate™ is effective in helping to break the chain of infection caused by the virus.

In addition, GK-GermKiller® Concentrate™ is also tested effective >99.9% against other common viruses such as Influenza A (H1N1) and Human Rotavirus. Furthermore, even at dilutions up to 80 parts of water, GK-GermKiller® Concentrate™ can still effectively inactivate >99.9% of illness-causing bacteria.

GK-GermKiller® Concentrate™ is also formulated to be safe for daily use around humans and animals alike, and on various surfaces, materials and the environment. The disinfectant was tested for its acute toxicity, irritation, and sensitisation based on OECD Guidelines for the Testing of Chemicals [5] and was deemed safe when the directions for use are followed. GK-GermKiller® Concentrate™ is a Green Label [6] product approved by the Singapore Environment Council to be an environmentally preferred surface cleaner. It is also a registered product in the NSF International Nonfood Compounds Registration Program Category C1 [7] which assess products for food processing establishments.

“Our rigorous international third-party testing assures our customers that GK-GermKiller® Concentrate™ is a quality and effective product they can trust,” says Damon Lim, Head of Sales.

Vance Chemical’s R&D and manufacturing are all located in Singapore and all GK-GermKiller® products are tested using international protocols by leading independent local and international laboratories.

More product information can be found at gk-germkiller.com.

[1] “Severe Acute Respiratory Syndrome Coronavirus 2 From Patient With Coronavirus Disease, United States”, Jennifer Harcourt, et. al., “Emerging Infectious Diseases. 2020;26(6):1266-1273.”, https://www.medscape.com/viewarticle/931155_4
[2] “ASTM E1053-20 Standard Practice to Assess Virucidal Activity of Chemicals Intended for Disinfection of Inanimate, Nonporous Environmental Surfaces”, ASTM International, https://www.astm.org/Standards/E1053.htm
[3] “How does COVID-19 spread between people”, World Health Organization, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19-how-is-it-transmitted
[4] “The effect of temperature on persistence of SARS-CoV-2 on common surfaces”, Shane Riddell, et. al., Virology Journal, DOI https://doi.org/10.1186/s12985-020-01418-7
[5] “OECD Guidelines for the Testing of Chemicals”, OECDiLibrary, https://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals_72d77764-en
[6] “Singapore Green Label”, Singapore Environment Council, https://sgls.sec.org.sg/cms.php?cms_id=3
[7] “Nonfood Compounds”, NSF International, https://www.nsfinternational.eu/food/non-food-compounds/

Swee Cheng Lim
Vance Chemicals Pte. Ltd
+65 6863 0863
email us here
Visit us on social media:

Source: EIN Presswire